Dive into some
exciting news

Dr. Chung is a renowned critical care physician, research and thought leader in extracorporeal life support therapies DENVER, CO and TAMPA, FL, May 24, 2022 — SeaStar Medical Inc., a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company, today announced that Kevin Chung, MD will join SeaStar Medical as Chief Medical Officer (CMO), effective July 1, 2022. Dr. Chung brings over 20 years of experience as an accomplished critical care physician with expertise in extracorporeal life support therapies (ECLS).

Designation helps enable accelerated regulatory review of upcoming pivotal clinical trial for treatment in adult patients with acute kidney injury DENVER, CO and TAMPA, FL, May 03, 2022 — SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (“LMAO”), a special purpose acquisition company, today announced that SeaStar Medical’s Selective Cytopheretic Device (SCD) has received a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The SCD is a patented, cell-directed, extracorporeal immunomodulator that selectively targets activated neutrophils and monocytes to address hyperinflammation. Neutrophils

SeaStar Medical is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs Transaction to provide SeaStar with access to the capital markets, allowing it to accelerate the development and advancement of its proprietary and innovative immunomodulatory platform for pediatric and adult acute kidney injury (AKI) SeaStar Medical plans to advance other programs for acute and chronic inflammations, including conditions associated with Covid-19 Dow Pension Plans, as existing investors of SeaStar Medical, commit to further participate in the transaction through a PIPE investment The proposed business combination is expected to be completed in the third

Results show promise for returning a dysregulated immune system to homeostasis in critically ill patients DENVER, CO, November 5, 2021— SeaStar Medical, a medical device company that has redefined how extracorporeal therapies may reduce excessive inflammation on vital organs, announced new data from its SCD 005 clinical study to evaluate the safety and feasibility of the Selective Cytopheretic Device (SCD) in COVID-19 patients with acute kidney injury (AKI) and/or acute respiratory distress syndrome (ARDS). The data were presented at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting. In the poster presentation, “SCD treatment in COVID-19 ICU Patients

— Board members are industry leaders who will actively support company growth strategies — DENVER, Jan. 11, 2021 /PRNewswire/ — SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, announced today it has appointed Rick Barnett and Dr. Allan J. Collins to its board of directors, effective January 8, 2021.  “We are excited and honored to welcome Rick and Allan as new independent directors to the SeaStar Medical board, ” said Ray Chow, Chair of the Board of Directors of SeaStar Medical. “They join SeaStar Medical at an important time as we transition to commercializing our Selective Cytopheretic (SCD) therapeutic device. Rick